Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reissue Patent
2007-09-25
2007-09-25
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S170000, C514S182000, C514S843000
Reissue Patent
active
10893795
ABSTRACT:
A method of female contraception involves administering a combination of estrogen and progestin for 60-110 consecutive days in which the daily amounts of estrogen and progestin are equivalent to about 5-35 mcg of ethinyl estradiol and about 0.025 to 10 mg of norethindrone acetate, respectively. The advantages include less menstrual bleeding, less patient anemia, less total exposure to medication, higher compliance rates and more lifestyle convenience for patients.
REFERENCES:
patent: 4145416 (1979-03-01), Lachnit-Fixson et al.
patent: 4390531 (1983-06-01), Edgren
patent: 4962098 (1990-10-01), Boissonneault
patent: 5098714 (1992-03-01), Wright et al.
patent: 5108995 (1992-04-01), Casper
patent: 5208225 (1993-05-01), Boissonneault et al.
patent: 5552394 (1996-09-01), Hodgen
patent: 5756490 (1998-05-01), Lachnit et al.
patent: RE36247 (1999-07-01), Plunkett et al.
patent: RE37838 (2002-09-01), Spona et al.
patent: 6500814 (2002-12-01), Hesch
patent: 2003/0018018 (2003-01-01), Hodgen et al.
patent: 2003/0139381 (2003-07-01), Bell et al.
patent: 2004/0220152 (2004-11-01), Ben-Maimon et al.
patent: 2004/0222123 (2004-11-01), Niemann
patent: 2004/0251301 (2004-12-01), Niemann et al.
patent: 2005/0051454 (2005-03-01), Coe et al.
patent: 2005/0064031 (2005-03-01), Stockemann et al.
patent: 2005/0143359 (2005-06-01), Bell et al.
patent: 0 253 607 (1988-01-01), None
patent: 0 911 029 (2003-09-01), None
patent: WO 93/17686 (1993-09-01), None
patent: WO 97/06807 (1997-02-01), None
patent: WO 98/04246 (1998-02-01), None
patent: WO 00/38691 (2000-07-01), None
patent: WO 2004/080442 (2004-09-01), None
patent: WO 2005/032558 (2005-04-01), None
Davies et al., Contraception, 46(3), 269-278 (1992).
Kovac et al. The British Journal of Family Planning, 19: 274-275 (1994).
Cachrimanidou et al., Contraception, 48, 205-216 (1993).
Loudon et al., British Medical Journal,2, 487-490 (1977).
Facts and Comparisons, chapter 3, pp. 108b-108e (1985).
Hipkin, L., Col., “The Induction of Amenorrhoea,”J.R. Army Med. Corps 138:15-18, Royal Army Medical Corps (1992).
Koetsawang, S., et al., “A Randomized, Double-Blind Study of Six Combined Oral Contraceptives,”Contraception 25:231-241, Elsevier (1982).
Kuhl, H., “Comparative Pharmacology of Newer Progestogens,”Drugs 51:189-215, ADIS International Ltd. (1996).
Rosenberg, M.J. and Waugh, M.S., “Oral contraceptive discontinuation: A prospective evaluation of frequency and reasons,”Am. J. Obstet. Gynecol. 179:577-582, Mosby, Inc. (1998).
Sheth, A., et al., “A Randomized, Double-Blind Study of Two Combined and Two Progestogen-Only Oral Contraceptives,”Contraception 25:243-252, Elsevier (1982).
Sulak, P.J., et al., “Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms,”Am. J. Obstet. Gynecol. 186:1142-1149, Mosby, Inc. (Jun. 2002).
Sulak, P.J., “Should your patient be on extended-use OCs?”Contemporary OB/GYN 48:35-46, Thomson Medical Economics (Sep. 2003).
“Headaches: OCs are ‘guilty by association’,”Contraceptive Technology Update 14(7):109-112, Thomson American Health Consultants (1993).
Goldzieher, J.W., “Use and Misuse of the Term Potency with Respect to Oral Contraceptives,”J. Reproductive Med. 31:533-539, The Journal of Reproductive Medicine, Inc. (1986).
King, R.J.B., and Whitehead, M.I., “Assessment of the potency of orally administered progestins in women,”Fertility and Sterility 46:1062-1066, Elsevier for the American Society for Reproductive Medicine (1986).
Kornaat, H., et al., “The Acceptance of a 7-Week Cycle with a Modern Low-Dose Oral Contraceptive (Minulet®),”Contraception 45:119-127, Elsevier (1992).
Mashchak, C.A., et al., “Comparison of pharmacodynamic properties of various estrogen formulations,”Am. J. Obstet. Gynecol. 144:511-518, The C.V. Mosby Co. (1982).
Miller, L., and Notter, K.M., “Menstrual Reduction With Extended Use of Combination Oral Contraceptive Pills: Randomized Controlled Trial,”Obstet. Gynecol. 98:771-778, Lippincott, Williams & Wilkins (Nov. 2001).
Phillips, A., et al., “A Comparison of the Potencies and Activities of Progestogens Used in Contraceptives,”Contraception 36:181-192, Geron-X, Inc. (1987).
Piper, J.M., and Kennedy, D.L., “Oral Contraceptives in the United States: Trends in Content and Potency,”Intl. J. Epidemiology 16:215-221, Oxford University Press (1987).
Shearman, R.P., “Oral contraceptive agents,”Med. J. Australia 144:201-205, Australasian Medical Publishing (1986).
Adams Hillard, P.J., “Oral contraception noncompliance: The extent of the problem,”Adv. Contracep. 8(Suppl. 1):13-20, Kluwer Academic Publishers (1992).
Coffee, A., “Hormone-Based Contraception: The Extended Cycle Regimen,” Supplement toDrug Topics, pp. 3-15, Advanstar Communications, Inc. (Jan. 2004).
Dickey, R.P., “Oral Contraception: Realizing the Promise by Overcoming the Pitfalls,”Individualizing Oral Contraceptive Therapy, OBG Management Supplement, pp. 2-6, Watson Pharma, Inc. (Oct. 2000).
Duramed Pharmaceuticals, Inc.
Spivack Phyllis G.
Sterne Kessler Goldstein & Fox P.L.L.C.
LandOfFree
Methods of extended use oral contraception does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of extended use oral contraception, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of extended use oral contraception will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3738450